A leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced three major developments at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) this week in Brussels, Belgium – one of the largest global conferences dedicated to critical care medicine:
- The introduction of HotSwap™ by CytoSorbents – The New CytoSorb exchange system
- The renewal of its long-standing partnership with Aferetica Srl in Italy, and
- New clinical data reinforcing the growing body of evidence supporting CytoSorb® therapy
CytoSorbents Launches HotSwap™ to Simplify and Optimize Therapy
CytoSorbents announced the immediate availability of HotSwap™, an innovative solution designed to enable rapid, seamless exchange of CytoSorb adsorbers during the treatment of critically-ill patients. HotSwap™ is designed to:
- Enable faster, easier device exchanges – particularly in high-acuity patients requiring frequent changes
- Facilitate the safe return of blood from used devices back to the patient
- Streamline workflows for ICU staff, reducing nursing burden and improving treatment consistency
“In critically ill patients, timing, dosing, and treatment intensity are essential to improving outcomes,” stated Dr. Phillip Chan, Chief Executive Officer of CytoSorbents. “HotSwap enables clinicians to more easily and efficiently treat the right patient, at the right time, with the right dose. Early user feedback has been highly positive, reinforcing our decision to make this technology broadly available.”
Dr. Chan added, “In life-threatening diseases such as sepsis, acute respiratory distress syndrome, liver failure, and trauma, unstable patients often require multiple device changes per day in the early phase of treatment to control deadly massive inflammation or to reduce high concentrations of toxic substances that can otherwise lead to organ failure and death. HotSwap makes this process faster, safer, and more practical, while preserving valuable blood volume and reducing the workload on ICU teams.”
CytoSorbents Renews Strategic Partnership with Aferetica
CytoSorbents also announced the renewal of its exclusive distribution agreement with Aferetica Srl in Italy, extending a successful collaboration spanning more than a decade. The partnership has supported widespread adoption of CytoSorb across critical care and cardiac surgery in Italy. The companies have also collaborated on Aferetica’s innovative PerLife® organ perfusion platform, which integrates CytoSorbents’ PerSorb® cartridge to improve organ preservation and rehabilitation for transplantation.
“Aferetica has been an exceptional long-term partner,” stated Dr. Chan. “CEO Mauro Atti and his team, working closely with leading clinicians and researchers in the country, have played a critical role in advancing both the clinical adoption and scientific understanding of CytoSorb therapy. We are excited to continue working together to expand innovation in blood purification and organ transplantation.”
Mr. Mauro Atti, Chief Executive Officer of Aferetica SRL stated, “We are happy to continue our successful collaboration with CytoSorbents that has contributed to the growth of our companies and importantly, the care and recovery of many patients. For more than ten years, we have shared the vision that blood purification can significantly improve outcomes in critically ill patients. Together we have successfully expanded from sepsis into liver failure and other critical illnesses, and now organ transplantation. We look forward to many more years of continued progress and shared success.”
Read Also: Health Care Organizations Press Congress to End MPPR Policy
